Letter
Oncology
Shuling Chen, Jiaxin Li, Aoran Dong, Zelong Liu, Meiyan Zhu, Meng Jin, Guangyan Wei, Shuang Wu, Yan Wang, Yong Chen, Zhenwei Peng
Summary: This study compared the efficacy and safety of combination therapy with immunotherapy and radiotherapy versus chemotherapy alone for patients with locally advanced pancreatic adenocarcinoma (LAPC). The combination treatment group showed significant advantages in median overall survival and progression-free survival compared to the chemotherapy alone group. However, the incidence of severe adverse events did not differ significantly between the two groups. Therefore, combination therapy appears to be an effective and safe treatment option for LAPC patients.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Article
Oncology
Satoshi Kobayashi, Motoko Suzuki, Makoto Ueno, Yuta Maruki, Naohiro Okano, Akiko Todaka, Masato Ozaka, Kunihiro Tsuji, Kazuhiko Shioji, Keitaro Doi, Yasushi Kojima, Hidetaka Tsumura, Kazunari Tanaka, Hajime Higuchi, Ken Kawabe, Hiroshi Imaoka, Tatsuya Yamashita, Haruo Miwa, Hiroaki Nagano, Shiho Arima, Hideyuki Hayashi, Atsushi Naganuma, Hironori Yamaguchi, Terumasa Hisano, Kumiko Umemoto, Shuji Ishii, Koji Nakashima, Rei Suzuki, Yohei Kitano, Toshihiro Misumi, Junji Furuse, Hiroshi Ishii
Summary: This study investigated the efficacy and safety of Gemcitabine plus nab-paclitaxel (GnP) compared to other treatments in older adults with unresectable pancreatic cancer (uPC). The results showed that GnP was more effective than Gem in patients aged 76 years and older, despite a higher incidence of severe adverse events.
Article
Gastroenterology & Hepatology
Volker Kunzmann, Jens T. Siveke, Hana Alguel, Eray Goekkurt, Gabriele Siegler, Uwe Martens, Dirk Waldschmidt, Uwe Pelzer, Martin Fuchs, Frank Kullmann, Stefan Boeck, Thomas J. Ettrich, Swantje Held, Ralph Keller, Ingo Klein, Christoph-Thomas Germer, Hubert Stein, Helmut Friess, Marcus Bahra, Ralf Jakobs, Ingo Hartlapp, Volker Heinemann
Summary: The study compared the efficacy and safety of two multidrug induction chemotherapy regimens for locally advanced pancreatic cancer and found that nab-paclitaxel plus gemcitabine is similarly active and safe as nab-paclitaxel plus gemcitabine followed by FOLFIRINOX. However, further evidence is needed to determine whether this translates into improved overall survival for patients.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2021)
Article
Oncology
Yuan Zong, Jiajia Yuan, Zhi Peng, Ming Lu, Xicheng Wang, Lin Shen, Jun Zhou
Summary: The study compared the efficacy and safety of nab-paclitaxel plus S-1 with nab-paclitaxel plus gemcitabine in first-line chemotherapy for patients with PDAC. Despite comparable efficacy, the nab-P/S combination showed improved safety profile with reduced risks of hematological toxicity, liver injury, and rash. There were no significant differences in primary and secondary endpoints between the two treatment arms.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Simon Zaibet, Vincent Hautefeuille, Edouard Auclin, Astrid Lievre, David Tougeron, Mathieu Sarabi, Marine Gilabert, Julie Wasselin, Julien Edeline, Pascal Artru, Dominique Bechade, Clemence Morin, Agnes Ducoulombier, Julien Taieb, Simon Pernot
Summary: This study evaluates the efficacy and safety of adding Nab-paclitaxel to Gem for metastatic pancreatic adenocarcinoma (mPA) after FOLFIRINOX failure. The results show that Gem-Nab is associated with better disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) compared with Gem alone, but with higher toxicity.
BRITISH JOURNAL OF CANCER
(2022)
Review
Oncology
Francesco Di Costanzo, Federica Di Costanzo, Lorenzo Antonuzzo, Ernesto Mazza, Elisa Giommoni
Summary: Choosing the best first-line treatment for metastatic pancreatic cancer is crucial in improving survival rate and quality of life. FOLFIRINOX and Nab-p plus Gem have been recognized as the most effective treatment regimens. FOLFIRINOX shows better efficacy but higher toxicity.
Article
Medicine, General & Internal
Tanios Bekaii-Saab, Takuji Okusaka, David Goldstein, Do-Youn Oh, Makoto Ueno, Tatsuya Ioka, Weijia Fang, Eric C. Anderson, Marcus S. Noel, Michele Reni, Hye Jin Choi, Jonathan S. Goldberg, Sang Cheul Oh, Chung-Pin Li, Josep Tabernero, Jian Li, Emma Foos, Cindy Oh, Eric Van Cutsem
Summary: In an open-label phase 3 study, it was found that the addition of napabucasin to nab-paclitaxel with gemcitabine did not improve efficacy in patients with previously untreated metastatic pancreatic adenocarcinoma (mPDAC). However, the safety profile of napabucasin was consistent with previous reports. This study reinforced the value of nab-paclitaxel plus gemcitabine as a platform for novel therapeutic approaches in mPDAC.
Article
Oncology
Konstantin Schlick, Antonia Gantschnigg, Alexander Seymer, Florian Huemer, Richard Greil, Lukas Weiss
Summary: This study compared the clinical efficacy of Gem-Nab and Gem-Ox in patients with pancreatic cancer and found no significant difference in survival rates and progression-free survival rates between the two regimens. Therefore, Gem-Ox can be considered as a potential first-line treatment option for inoperable advanced pancreatic cancer.
Review
Multidisciplinary Sciences
Yoon Suk Lee, Jong-chan Lee, Jae-Hyeong Kim, Jaihwan Kim, Jin-Hyeok Hwang
Summary: The treatment outcomes of FOLFIRINOX and GNP as first-line chemotherapy regimens for metastatic pancreatic cancer vary between Western and Asian subgroups, with Western patients showing higher survival benefit from FOLFIRINOX and Asian patients showing higher survival benefit from GNP.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Masato Ozaka, Kohei Nakachi, Satoshi Kobayashi, Akihiro Ohba, Hiroshi Imaoka, Takeshi Terashima, Hiroshi Ishii, Junki Mizusawa, Hiroshi Katayama, Tomoko Kataoka, Takuji Okusaka, Masafumi Ikeda, Naoki Sasahira, Haruo Miwa, Eishiro Mizukoshi, Naohiro Okano, Nobumasa Mizuno, Tomohisa Yamamoto, Yoshito Komatsu, Akiko Todaka, Ken Kamata, Masayuki Furukawa, Nao Fujimori, Akio Katanuma, Yukiko Takayama, Hidetaka Tsumura, Haruhiko Fukuda, Makoto Ueno, Junji Furuse
Summary: The aim of this study was to compare the efficacy of mFOLFIRINOX with that of GnP for LAPC. The results showed that GnP had better response rate, CA19-9 response, and mild gastrointestinal toxicities, making it a candidate for a subsequent phase III trial.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Feng Zhang, Yuyang Wang, Fangfang Yang, Yuming Zhang, Man Jiang, Xiaochun Zhang
Summary: This study evaluated the efficacy and safety of PD-1 inhibitor combined with nab-paclitaxel plus gemcitabine (AG) chemotherapy versus AG chemotherapy in the first-line treatment of advanced pancreatic cancer. The results showed that PD-1 inhibitor combined with AG chemotherapy significantly improved overall survival and had good efficacy in patients with KRAS and TP53 co-mutations.
CANCER MANAGEMENT AND RESEARCH
(2022)
Article
Oncology
Nicolas Williet, Angelica Petrillo, Gael Roth, Michele Ghidini, Mila Petrova, Julien Forestier, Anthony Lopez, Audrey Thoor, Lucie Weislinger, Ferdinando De Vita, Julien Taieb, Jean Marc Phelip
Summary: Gemcitabine/nab-paclitaxel (GN) and FOLFIRINOX (FFX) were found to have no significant difference as first-line treatments in patients with locally advanced pancreatic cancer (LAPC) in terms of survival, tumor response, or tumor resection rate, according to a multicenter European study. Further trials are needed to confirm these findings.
Article
Biochemistry & Molecular Biology
Ilario Giovanni Rapposelli, Andrea Casadei-Gardini, Caterina Vivaldi, Giulia Bartolini, Laura Bernardini, Alessandro Passardi, Giovanni Luca Frassineti, Valentina Massa, Alessandro Cucchetti
Summary: The study found that FFX and GN have equivalent efficacy in first-line treatment of metastatic pancreatic cancer, but differ in safety profiles. Anemia was more frequent in the GN group, while higher occurrences of vomiting and diarrhea were reported in the FFX group.
Article
Medicine, General & Internal
Avital Klein-Brill, Shlomit Amar-Farkash, Gabriella Lawrence, Eric A. Collisson, Dvir Aran
Summary: This study compared the two common first-line treatments for metastatic adenocarcinoma of the pancreas, FOLFIRINOX and gemcitabine plus nab-paclitaxel, and found that FOLFIRINOX was associated with improved overall survival and fewer posttreatment complications.
Article
Oncology
Stefano Cascinu, Rossana Berardi, Roberto Bianco, Domenico Bilancia, Alberto Zaniboni, Daris Ferrari, Stefania Mosconi, Andrea Spallanzani, Luigi Cavanna, Silvana Leo, Francesca Negri, Giordano D. Beretta, Alberto Sobrero, Maria Banzi, Alberto Morabito, Alessandro Bittoni, Roberta Marciano, Domenica Ferrara, Silvia Noventa, Maria C. Piccirillo, Roberto Labianca, Cristina Mosconi, Andrea Casadei Gardini, Ciro Gallo, Francesco Perrone
Summary: The combination chemotherapy regimen of Nab-paclitaxel and Gemcitabine showed superior efficacy compared to Gemcitabine alone in patients with unresectable locally advanced pancreatic cancer, reducing disease progression rate and distant relapses, and improving progression-free survival. This randomized trial provides evidence supporting the use of combination chemotherapy in this setting.
EUROPEAN JOURNAL OF CANCER
(2021)
